JA
PGNX

JOYN Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

JOYN Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-545
Closed -$2K – 1661
2018
Q4 		$2K Buy
545
+465
+581% +$2.37K ﹤0.01% 1564
2018
Q3 		$1K Sell
80
-124
-61% -$953 ﹤0.01% 1710
2018
Q2 		$2K Buy
204
+151
+285% +$1.15K ﹤0.01% 1487
2018
Q1 		$0 Buy
+53
New +$352 ﹤0.01% 1451

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JOYN Advisors's PGNX Position: Q1 2019 in Review

JOYN Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 545 shares — an estimated $2K sold.

JOYN Advisors first reported a position in PGNX in Q1 2018 and held it in 4 quarters. The position peaked at $2K in Q4 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • JOYN Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • JOYN Advisors sold 545 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $2K.
  • JOYN Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 4 quarters.
  • JOYN Advisors's Progenics Pharmaceuticals Inc position peaked at $2K in Q4 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.